Extract

THE U.S. FOOD AND DRUG ADMINISTRATION approved Belviq (lorcaserin hydrochloride), as an addition to a reduced-calorie diet and exercise, for adults with a body mass index (BMI) of 30 or greater (obese) or adults with a BMI of 27 or greater (overweight) with at least one weight-related comorbid condition such as hypertension, type 2 diabetes, or high cholesterol. The last weight loss drug to be approved by the agency was Xenical (orlistat) in 1999.

(http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm)

LOW BONE MASS WAS FOUND IN HIV-INFECTED young men on antiretroviral therapy, particularly those on regimens that included a protease inhibitor.

(Clin Infect Dis [August 1, 2012] 55:461)

DAILY SUPPLEMENTATION WITH N–3 FATTY ACIDS did not reduce the rate of death from cardiovascular causes in patients with dysglycemia and a high risk for cardiovascular events.

(N Engl J Med [published online June 11, 2012])

A COMBINED THERAPY OF METFORMIN AND ROSIGLITAZONE, compared to metformin alone or lifestyle intervention, helped maintain the best glycemic control in children and adolescents with type 2 diabetes.

You do not currently have access to this article.